Clinical Trials Research Institute | Thousand Oaks, CA

Research site

(Unclaimed)

Location

3095 Old Conejo Road Suite 204, Thousand Oaks, California, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Dupilumab

Difamilast

Lutikizumab

Risankizumab

SAR443765

Povorcitinib

Spesolimab

Lunsekimig

RPT193

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 18 total trials

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo 1

Drug: Placebo 2

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib Dose B

Drug: Upadacitinib Dose A

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting

Vitiligo

Drug: Upadacitinib

Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

Locations recently updated

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid)

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling

Hidradenitis Suppurativa

Drug: Lutikizumab

Drug: Placebo

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo

Biological: Lutikizumab

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Active, not recruiting

NonSegmental Vitiligo

Drug: Povorcitinib

Drug: Placebo

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Active, not recruiting

Alopecia Areata

Drug: Upadacitinib

Drug: Placebo

Status recently updated

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lun...

Not yet enrolling

Enrolling

Dermatitis Atopic

Drug: Lunsekimig

Drug: Placebo

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or st...

Active, not recruiting

Hidradenitis Suppurativa (HS)

Drug: Spesolimab

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...

Active, not recruiting

Atopic Dermatitis

Psoriasis

Biological: XmAb27564

Biological: Placebo

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and...

Active, not recruiting

Androgenetic Alopecia

Drug: PP405 Topical Vehicle Gel

Drug: PP405 0.05% Topical Gel

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (UnlIMMited)

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Active, not recruiting

Scalp Psoriasis

Genital Psoriasis

Drug: Risankizumab

Drug: Placebo for Risankizumab